- Home
- VRCA vs ECOR Comparison
VRCA vs ECOR Comparison
Compare VRCA & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- ECOR
- Stock Information
- Founded
- VRCA 2013
- ECOR 2005
- Country
- VRCA United States
- ECOR United States
- Employees
- VRCA N/A
- ECOR N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- VRCA Health Care
- ECOR Health Care
- Exchange
- VRCA Nasdaq
- ECOR Nasdaq
- Market Cap
- VRCA 43.0M
- ECOR 50.1M
- IPO Year
- VRCA 2018
- ECOR 2018
- Fundamental
- Price
- VRCA $0.54
- ECOR $5.09
- Analyst Decision
- VRCA Hold
- ECOR Strong Buy
- Analyst Count
- VRCA 5
- ECOR 2
- Target Price
- VRCA $6.00
- ECOR $25.50
- AVG Volume (30 Days)
- VRCA 263.8K
- ECOR 182.1K
- Earning Date
- VRCA 05-13-2025
- ECOR 05-07-2025
- Dividend Yield
- VRCA N/A
- ECOR N/A
- EPS Growth
- VRCA N/A
- ECOR N/A
- EPS
- VRCA N/A
- ECOR N/A
- Revenue
- VRCA $7,179,000.00
- ECOR $26,458,000.00
- Revenue This Year
- VRCA $127.85
- ECOR $26.76
- Revenue Next Year
- VRCA $105.09
- ECOR $44.87
- P/E Ratio
- VRCA N/A
- ECOR N/A
- Revenue Growth
- VRCA N/A
- ECOR 41.54
- 52 Week Low
- VRCA $0.38
- ECOR $4.47
- 52 Week High
- VRCA $9.36
- ECOR $19.49
- Technical
- Relative Strength Index (RSI)
- VRCA 43.40
- ECOR 39.64
- Support Level
- VRCA $0.49
- ECOR $4.77
- Resistance Level
- VRCA $0.73
- ECOR $5.49
- Average True Range (ATR)
- VRCA 0.07
- ECOR 0.44
- MACD
- VRCA -0.01
- ECOR 0.08
- Stochastic Oscillator
- VRCA 10.77
- ECOR 41.08
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About ECOR electroCore Inc.
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.